BioVersys AG | Finanzwire

Basculer en Français

11266	Companies
250321	Keywords
178887	Articles
136209	Press releases

Home
Companies
BioVersys AG

BRIEF

published on 07/02/2025 at 07:05, 1 year 4 months ago

BioVersys and Shionogi Collaborate on NTM Clinical Candidate

Global Commercialization BioVersys Collaboration Shionogi Partnership NTM Clinical Candidate Ansamycin Platform
PRESS RELEASE

published on 07/02/2025 at 07:00, 1 year 4 months ago

BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE
BioVersys and Shionogi enter global research collaboration for NTM clinical candidate. BioVersys grants Shionogi license option for leads from BV500 program

Shionogi BioVersys Global Research Collaboration NTM Clinical Candidate
BRIEF

published on 06/30/2025 at 07:05, 1 year 4 months ago

BioVersys AG Annual General Meeting Yields Positive Outcomes

Financial Statements Strategic Initiatives Board Elections BioVersys AGM Capital Amendment
PRESS RELEASE

published on 06/30/2025 at 07:00, 1 year 4 months ago

BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS
BioVersys AG announces results from its Annual General Meeting of Shareholders, including re-election of Board Members and amendment to capital range for strategic initiatives

Annual General Meeting Shareholders Board Members BioVersys AG Capital Range
BRIEF

published on 06/03/2025 at 07:05, 1 year 5 months ago

BioVersys Announces 2025 Annual General Meeting of Shareholders

Capital Increase Board Elections Shareholders Meeting 2025 AGM BioVersys AG
PRESS RELEASE

published on 06/03/2025 at 07:00, 1 year 5 months ago

BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 2025
BioVersys AG publishes Invitation to its Annual General Meeting of Shareholders 2025, including agenda with items such as annual report, elections, compensation approval, and capital range amendment

Annual General Meeting Shareholders Biopharmaceutical AGM 2025 BioVersys AG
BRIEF

published on 04/28/2025 at 07:05, 1 year 6 months ago

BioVersys to Host Virtual Event on BV100 Study for VABP

Virtual Event BioVersys AG BV100 Study VABP Treatment Carbapenem Resistance
PRESS RELEASE

published on 04/28/2025 at 07:00, 1 year 6 months ago

BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter on May 7, 2025
BioVersys AG to host virtual KOL event featuring Prof. David Paterson & Dr. Andrew Shorr on BV100 Phase 2 VABP study against CRAB. Register for insights on May 7, 2025

Virtual Event BioVersys AG Antibacterial Products Multidrug-resistant Bacteria Key Opinion Leaders
BRIEF

published on 04/08/2025 at 07:05, 1 year 6 months ago

BioVersys to Showcase BV100 Data at ESCMID Global 2025

Clinical Trial Antibiotic Resistance BV100 BioVersys ESCMID 2025
PRESS RELEASE

published on 04/08/2025 at 07:00, 1 year 6 months ago

BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025
BioVersys to present BV100 Phase 2 data at 35th ESCMID Global 2025. Oral presentation on positive VABP trial read-out & poster presentations on Acinetobacter baumannii & NTM data

Clinical Data BV100 Antibacterial Products BioVersys ESCMID Global 2025

Accesswire

Published on 11/03/2026 at 22:25, 14 minutes ago

Globe Takes Major Step Toward AI-Driven Services with Amdocs Data Modernization Program
Published on 11/03/2026 at 22:20, 19 minutes ago

Magyar Telekom Selects Amdocs to Deliver Billing Transformation and Catalog Modernization
Published on 11/03/2026 at 22:15, 24 minutes ago

Globe Expands Strategic Collaboration with Amdocs to Modernize Core Platforms and Strengthen IT Operations
Published on 11/03/2026 at 22:10, 29 minutes ago

Vodafone Business UK Selects Amdocs to Drive Agentic Transformation of B2B Operations with aOS
Published on 11/03/2026 at 22:05, 34 minutes ago

Integratel Perú Expands Collaboration with Amdocs to Improve Operational Efficiency and Accelerate Service Innovation

View all ACCESSWIRE

EQS Group

Published on 11/03/2026 at 22:10, 29 minutes ago

BIRKENSTOCK ANNOUNCES FOURTH QUARTER AND FULL FISCAL YEAR 2026 (ENDED SEPTEMBER 30, 2026) RESULTS DATE AND CONFERENCE CALL SCHEDULED FOR DECEMBER 10, 2026
Published on 11/03/2026 at 19:30, 3 hours 9 minutes ago

Africa and Caribbean trade potential could reach $1.65 billion annually by 2030: International Trade Centre (ITC)-Afreximbank report
Published on 11/03/2026 at 18:00, 4 hours 39 minutes ago

ROCTOOL: new significant €6.5 Million order
Published on 11/03/2026 at 17:45, 4 hours 54 minutes ago

BILENDI: Bilendi returns to slight revenue growth in Q3 2026
Published on 11/03/2026 at 17:34, 5 hours 5 minutes ago

EQS-Adhoc: fox e-mobility AG: Convocation AGM 2026 with proposed resolutions for capital increases in the vehicle production and wind energy sectors and presentation of the 2025 annual statements

Les Echos

Published on 11/03/2026 at 18:00, 4 hours 39 minutes ago

Outstanding Shares and Voting Rights Monthly Statement - 31 October 2026
Published on 11/03/2026 at 17:45, 4 hours 54 minutes ago

Declaration of voting rights at the end of October 2026
Published on 11/03/2026 at 07:00, 15 hours 39 minutes ago

bioMérieux – Third-Quarter 2026 Business Review
Published on 11/02/2026 at 21:08, 1 day 1 hour ago

GROUPE SFPI LIQUIDIDY CONTRAT H1 2026
Published on 11/02/2026 at 18:30, 1 day 4 hours ago

Disclosure of transactions in own shares from October 26 to October 30, 2026

View all LES ECHOS COMFI WIRE